Laboratory monitoring for spironolactone in congestive heart failure

Cardiology Review

Volumn 23, Issue 6, 2006, Pages 35-37

  Shah, Keyur B ^a   Gottlieb, Stephen S ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MINERALOCORTICOID RECEPTOR; POTASSIUM; SPIRONOLACTONE;

ADULT; ARTICLE; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG MONITORING; FEMALE; FOLLOW UP; HUMAN; HYPERKALEMIA; KIDNEY DISEASE; KIDNEY FUNCTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; POTASSIUM BLOOD LEVEL;

EID: 33745222086     PISSN: 10926607     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (3)

1. Pitt B, Zannad F, Remme WJ, et al for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1993;341(10):709-717.
2. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351 (6):543-551.
3. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old meicine spirals out of new guidelines. J Am Coll Cardiol. 2003;41(2):211-214.